Sarah C. Rutherford, MD | Authors


DLBCL Cell of Origin: What Role Should It Play in Care Today?

September 18, 2018

In this article, we review the methods of determining cell of origin (COO); use of COO in clinical practice; clinical trials in DLBCL according to COO; and future directions of tailoring treatment, including alternate categorization of genetic subtypes or clusters in DLBCL.

The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval

May 15, 2017

Given the benefit of rituximab to patients, it will be important that the use of biosimilar compounds not compromise the efficacy of treatment. However, measures to improve access to anti-CD20 therapy in a cost-effective manner will clearly provide benefit to patients with lymphoma.